Overcoming Multidrug Resistance by Bacterial Efflux Pump Inhibitors in Clinical Escherichia coli Strains
Open Access
- 9 March 2026
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 15 (3) , 276
Abstract
Background/Objectives: Antimicrobial resistance (AMR) is an escalating global threat driven by antibiotic misuse and bacterial adaptation. Efflux pumps are major contributors to multidrug resistance in Escherichia coli, as they expel antibiotics and reduce their intracellular activity. This study examined efflux-mediated resistance in extended-spectrum beta-lactamase (ESBL)-producing E. coli and evaluated the potential of several efflux pump inhibitors (EPIs)—promethazine (PMZ), thioridazine (TZ), carbonyl cyanide m-chlorophenyl hydrazine (CCCP), reserpine (RES), and phenyl-arginine-β-naphthylamide (PAβN)—as therapeutic adjuncts. Methods: Antibacterial and anti-biofilm activities of EPIs were tested using broth microdilution, real-time fluorimetry, and crystal violet assays, while ceftriaxone–PMZ interactions were assessed by checkerboard analysis. Results: TZ and CCCP showed strain-specific antibacterial activity, whereas PMZ, RES, and PAβN did not exert any effect. PMZ, TZ, and especially CCCP effectively inhibited efflux pump function, while RES and PAβN were less active. Biofilm inhibition varied between strains, with PMZ and TZ producing moderate reductions. We observed a quite weak synergism between ciprofloxacin, ceftriaxone, and PMZ; however, the result was not significant. Conclusions: Overall, the results highlight the central role of efflux pumps in ESBL-producing E. coli and indicate that EPIs can reverse resistance (e.g., PMZ) and exhibit potent anti-biofilm activity and show additive interactions with antibiotics. However, further studies are needed to optimize their safety, pharmacokinetics, and antibiotic pairing for potential clinical use.Keywords
Funding Information
- Albert Szent-Györgyi Medical School, University of Szeged, Hungary (SZTESZAOK-KKASZGYA2023/5S772)
- University Research Scholarship Programme (EKÖP), Ministry of Culture and Innovation, National Research, Development and Innovation Fund (EKÖP-348-SZTE)
This publication has 45 references indexed in Scilit:
- Understanding the role of drug efflux pumps in biofilms and virulence properties: Multiple potential strategies controlling bacterial infectionsInternational Journal of Antimicrobial Agents, 2025
- Antimicrobial resistance: Impacts, challenges, and future prospectsJournal of Medicine, Surgery, and Public Health, 2024
- Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicityInternational Journal of Infectious Diseases, 2013
- Histamine and H1-antihistamines: Celebrating a century of progressJournal of Allergy and Clinical Immunology, 2011
- An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulatorsInternational Journal of Antimicrobial Agents, 2009
- Mechanisms of drug efflux and strategies to combat them: Challenging the efflux pump of Gram-negative bacteriaBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2009
- Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activitiesInternational Journal of Antimicrobial Agents, 2008
- Promethazine renders Escherichia coli susceptible to penicillin G: real-time measurement of bacterial susceptibility by fluoro-luminometryInternational Journal of Antimicrobial Agents, 2007
- Practical applications and feasibility of efflux pump inhibitors in the clinic—A vision for applied useBiochemical Pharmacology, 2006
- Synergistic effect of promethazine with gentamycin in frequently recurring pyelonephritisInternational Urology and Nephrology, 1990